Document is current

Article History

Received: 4 March 2025

Accepted: 24 April 2025

First Online: 16 May 2025

Declarations

:

: Yusuke Miyazaki has received consulting fees, speaking fees, and/or honoraria from Eli Lilly and has received research grants from GlaxoSmithKline. Koshiro Sonomoto has received speaking fee from Abbvie, Eli Lilly Japan, Gilead Sciences, GlaxoSmithKline, Janssen, Pfizer Japan, UCB Japan, Astellas, Ayumi, Chugai, Taisho, Tanabe Mitsubishi and has received research funding from UCB Japan. Satoshi Kubo has received speaking fees from Eli Lilly, Bristol-Myers, GlaxoSmithKline, Abbvie, and also research grants from Daiichi-Sankyo, Abbvie, Boehringer Ingelheim, and Astellas. Masanobu Ueno has received speaking fee and honoraria from GlaxoSmithKline. Shingo Nakayamada has received speaking fees and/or honoraria from GlaxoSmithKline, Astellas Pharma, Eli Lilly, AbbVie, Mitsubishi Tanabe Pharma, Janssen, Pfizer, Bristol Myers Squibb, Asahi- Kasei, Chugai Pharmaceutical, AstraZeneca, Taisho Pharmaceutical, Eisai, Gilead Sciences, UCB and Ayumi and has received consulting fees, lecture fees from Asahi- Kasei, Otsuka Pharmaceutical and Mitsubishi Tanabe Pharma. Yoshiya Tanaka has received consulting fees, speaking fees, and honoraria from Behringer-Ingelheim, Eli Lilly, Abbvie, Gilead, AstraZeneca, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe, and GlaxoSmithKline, and has received research grants from Asahi-Kasei, Abbvie, Chugai, Eisai, Takeda, Daiichi-Sankyo, and Boehringer Ingelheim. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. During the completion of the manuscript, Y.Tanaka’s affiliation changed as follows: Department of Molecular Target Therapy, School of Medicine, Occupational and Environmental Medicine, Japan. Atsushi Nagayasu, Ippei Miyagawa, Ayako Yamaguchi, Hiroaki Tanaka, Yasuyuki Todoroki, Takafumi Aritomi, Yuya Fujita, Hidenori Sakai, and Katsunori Suzuki have nothing to disclose.

: This study complied with the Declaration of Helsinki and received approval from the ethical review board of the University of Occupational and Environmental Health, Japan (Approval number UOEHCRB21-068). Informed consent was obtained from the patients included in the analysis for their registration in the FIRST registry.